Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 2/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.32 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2580621 | 0.70 | HTR1A (0.31) | HTR1ACYP3A4TSHR | |
| Water SCHEMBL30136134 | 0.66 | — | — | |
| SCHEMBL4421682 | 0.66 | HTR1A (0.46) | HTR1ADRD2CYP3A4TSHRKDM4E | |
| SCHEMBL10967544 | 0.65 | CA12 (0.41) | HTR1ADRD2CYP3A4TSHRCA12 | |
| SCHEMBL11542044 | 0.64 | ALKBH5 (0.37) | KDM4EALDH1A1HPGD | |
| SCHEMBL1649877 | 0.64 | — | — | |
| SCHEMBL5656874 | 0.63 | HTR1A (0.32) | HTR1A | |
| SCHEMBL11207376 | 0.63 | HPGD (0.55) | HTR1ADRD2KDM4EALDH1A1HPGD | |
| SCHEMBL9378743 | 0.62 | CA12 (0.30) | CA12BRD4BRPF1CA9KAT2B | |
| SCHEMBL5982877 | 0.61 | HTR1A (0.36) | HTR1ADRD2CA12BRD4BRPF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230089412-A1 | METHODS OF TREATING CANCER PATIENTS WITH FARNESYLTRANSFERASE INHIBITORS | KURA ONCOLOGY INC (US) | 2023-03-23 | — | — | US | disclosed |
| US-11559540-B2 | Method of determining acute myeloid leukemia response to treatment with farnesyltransferase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2023-01-24 | — | — | US | disclosed |
| US-20220143006-A1 | METHODS OF TREATING CANCER WITH FARNESYLTRANSFERASE INHIBITORS | KURA ONCOLOGY, INC. | 2022-05-12 | — | — | US | disclosed |
| EP-3995589-A1 | METHODS OF TREATING CANCER PATIENTS WITH FARNESYL TRANSFERASE INHIBITORS | Kura Oncology, Inc. (US) | 2022-05-11 | — | — | EP | disclosed |
| US-20150302140-A1 | IN SILICO IDENTIFICATION OF CANCER MOLECULAR SIGNALING PATHWAYS AND DRUG CANDIDATES | H. LEE MOFFIT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2015-10-22 | — | — | US | disclosed |
| WO-2014071316-A1 | IN SILICO IDENTIFICATION OF CANCER MOLECULAR SIGNALING PATHWAYS AND DRUG CANDIDATES | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2014-05-08 | — | — | WO | disclosed |
| EP-2598874-A2 | METHODS OF DETERMINING ACUTE MYELOID LEUKEMIA RESPONSE TO TREATMENT WITH FARNESYLTRANSFERASE INHIBITORS | Veridex, LLC (US) | 2013-06-05 | — | — | EP | disclosed |
| WO-2012016021-A2 | METHODS OF DETERMINING ACUTE MYELOID LEUKEMIA RESPONSE TO TREATMENT WITH FARNESYLTRANSFERASE INHIBITORS | VERIDEX, LLC (US) | 2012-02-02 | — | — | WO | disclosed |
| US-20070148185-A1 | Novel therapeutic target for protozoal diseases | VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY | 2007-06-28 | — | — | US | disclosed |
| EP-1631285-A4 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | EURO CELTIQUE SA (LU) | 2006-11-02 | — | — | EP | disclosed |
| EP-1631285-A1 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | Euro-Celtique, S.A. (LU) | 2006-03-08 | — | — | EP | disclosed |
| WO-2005004866-A1 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | EURO-CELTIQUE, S.A. (LU) | 2005-01-20 | — | — | WO | disclosed |